Literature DB >> 15757900

JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation.

Hema Rangaswami1, Anuradha Bulbule, Gopal C Kundu.   

Abstract

We have recently demonstrated that nuclear factor-inducing kinase (NIK) plays a crucial role in osteopontin (OPN)-induced mitogen-activated protein kinase/I kappa B alpha kinase-dependent nuclear factor kappa B (NF kappa B)-mediated promatrix metalloproteinase-9 activation (Rangaswami, H., Bulbule, A., and Kundu, G. C. (2004) J. Biol. Chem. 279, 38921-38935). However, the molecular mechanism(s) by which OPN regulates NIK/MEKK1-dependent activating protein-1 (AP-1)-mediated promatrix metalloproteinase-9 activation and whether JNK1 plays any role in regulating both these pathways that control the cell motility are not well defined. Here we report that OPN induces alpha v beta3 integrin-mediated MEKK1 phosphorylation and MEKK1-dependent JNK1 phosphorylation and activation. Overexpression of NIK enhances OPN-induced c-Jun expression, whereas overexpressed NIK had no role in OPN-induced JNK1 phosphorylation and activation. Sustained activation of JNK1 by overexpression of wild type but not kinase negative MEKK1 resulted in suppression of ERK1/2 activation. But this did not affect the OPN-induced NIK-dependent ERK1/2 activation. OPN stimulated both NIK and MEKK1-dependent c-Jun expression, leading to AP-1 activation, whereas NIK-dependent AP-1 activation is independent of JNK1. OPN also enhanced JNK1-dependent/independent AP-1-mediated urokinase type plasminogen activator (uPA) secretion, uPA-dependent promatrix metalloproteinase-9 (MMP-9) activation, cell motility, and invasion. OPN stimulates tumor growth, and the levels of c-Jun, AP-1, urokinase type plasminogen activator, and MMP-9 were higher in OPN-induced tumor compared with control. To our knowledge this is first report that OPN induces NIK/MEKK1-mediated JNK1-dependent/independent AP-1-mediated pro-MMP-9 activation and regulates the negative crosstalk between NIK/ERK1/2 and MEKK1/JNK1 pathways that ultimately controls the cell motility, invasiveness, and tumor growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757900     DOI: 10.1074/jbc.M414204200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.

Authors:  Chun-Ying Wu; Ming-Shiang Wu; En-Pei Chiang; Cheng-Chung Wu; Yi-Ju Chen; Chien-Jen Chen; Nai-Hui Chi; Gran-Hum Chen; Jaw-Town Lin
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

2.  Lowered HGK expression inhibits cell invasion and adhesion in hepatocellular carcinoma cell line HepG2.

Authors:  Su-Xia Han; Qing Zhu; Jin-Lu Ma; Jing Zhao; Chen Huang; Xi Jia; Dan Zhang
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

3.  Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.

Authors:  Stephen M Selkirk; Jay Morrow; Tara A Barone; Alan Hoffer; Jeffrey Lock; Anne DeChant; Saisho Mangla; Robert J Plunkett; Robert H Miller
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

4.  The role of osteopontin in the development of albuminuria.

Authors:  Johan Lorenzen; Rajshree Shah; Alisha Biser; Serban A Staicu; Thiruvur Niranjan; Ana Maria Garcia; Antje Gruenwald; David B Thomas; Ibrahim F Shatat; Katarine Supe; Robert P Woroniecki; Katalin Susztak
Journal:  J Am Soc Nephrol       Date:  2008-05       Impact factor: 10.121

5.  Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.

Authors:  Johan M Lorenzen; Celina Schauerte; Anika Hübner; Malte Kölling; Filippo Martino; Kristian Scherf; Sandor Batkai; Karina Zimmer; Ariana Foinquinos; Tamas Kaucsar; Jan Fiedler; Regalla Kumarswamy; Claudia Bang; Dorothee Hartmann; Shashi K Gupta; Jan Kielstein; Andreas Jungmann; Hugo A Katus; Frank Weidemann; Oliver J Müller; Hermann Haller; Thomas Thum
Journal:  Eur Heart J       Date:  2015-04-21       Impact factor: 29.983

6.  Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.

Authors:  Lei Cao; Xiaoyu Fan; Wei Jing; Yingchao Liang; Rui Chen; Yingying Liu; Minhui Zhu; Rongjie Jia; Hao Wang; Xueguang Zhang; Yanyun Zhang; Xuyu Zhou; Jian Zhao; Yajun Guo
Journal:  Oncotarget       Date:  2015-03-30

7.  Cancer-associated Fibroblast-derived IL-6 Promotes Head and Neck Cancer Progression via the Osteopontin-NF-kappa B Signaling Pathway.

Authors:  Xing Qin; Ming Yan; Xu Wang; Qin Xu; Xiaoning Wang; Xueqin Zhu; Jianbo Shi; Zhihui Li; Jianjun Zhang; Wantao Chen
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

8.  Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis.

Authors:  Renzhi Wang; Yakun Yang; Miaomiao Sheng; Dechao Bu; Fengming Huang; Xiaohai Liu; Cuiqi Zhou; Congxin Dai; Bowen Sun; Jindong Zhu; Yi Qiao; Yong Yao; Huijuan Zhu; Lin Lu; Hui Pan; Ming Feng; Kan Deng; Bing Xing; Wei Lian; Yi Zhao; Chengyu Jiang
Journal:  Int J Mol Sci       Date:  2016-09-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.